semaglutide gallatin tn TennCare's obesity medication coverage is a win for Tennesseans • Tennessee Lookout MOORE LIFE URGENT CARE -

For broader options, see our Medical Weight Loss Services

1 The proportion achieving clinically meaningful weight loss: What about higher doses of semaglutide

J Clin Immunol 2004

Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously

Finding Support While you may choose not to be open with friends or family about your weight loss journeycompletely a personal decisionit can help to find and talk to others using GLP-1 medications to lose weight too

Sepsis alters the intestinal microenvironment, promoting epithelial cell barrier disruption, inflammation and bacterial translocation, leading to enteric infections